ncRNA basic information
ncRNA ID:
MIMAT0000074
ncRNA Database:
miRBase
ncRNA Name:
miR-19b-3p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
PIK3CA
ncRNA Pathway:
PI3K/Akt pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB11805
Drug Name:
Saracatinib
Drug Method:
In this study, we established a Src inhibitor saracatinib-resistant breast cancer cell line (SK-BR-3/SI) for the first time. Microarray data and qRT-PCR results showed that miR-19b-3p expression was downregulated in saracatinib-resistant cells compared with saracatinib-sensitive cells. Downregulation of miR-19b-3p remarkably increased the IC50 value of saracatinib, and promoted cell migration. Further studies found that miR-19b-3p reduced PIK3CA expression by directly targeting PIK3CA gene and the resistance of Src inhibitor might be associated with activation of PI3K/Akt pathway after downregulation of miR-19b-3p. Moreover, we demonstrated that PI3K inhibitor LY294002 could reverse saracatinib resistance in saracatinib-resistant cells, which deserved further preclinical and clinical evaluation of dual inhibition of Src and PI3K in breast cancer.
Drug Response:
sensitive
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line ( MDA-MB-231, SK-BR-3, BT-474 and MCF-7)
Other information
Title:
miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Journal:
Arch Biochem Biophys
Published:
2018
PubMed ID:
29550144